Trav3n-3 Inhibitors
Trav3n-3 inhibitors represent a chemical class of compounds that specifically interact with the Trav3n-3 protein or receptor, preventing its normal biological activity by inhibiting its function. These inhibitors typically bind to the active site of Trav3n-3, blocking the interaction with its natural substrate or ligand. In some cases, Trav3n-3 inhibitors may act through allosteric inhibition, where they bind to a site other than the active site, inducing conformational changes that reduce or block the protein's functional activity. The interactions between Trav3n-3 inhibitors and their target protein involve a variety of non-covalent forces such as hydrogen bonds, van der Waals forces, hydrophobic interactions, and electrostatic interactions. These forces ensure that the inhibitor fits precisely into the binding pocket of the protein, stabilizing the inhibitor-protein complex and preventing the protein from engaging in its regular activity.
Structurally, Trav3n-3 inhibitors are diverse, with designs ranging from small organic molecules to more complex entities like peptides or larger biomolecules. Key chemical features often include aromatic rings, heteroatoms such as nitrogen or oxygen, and functional groups like hydroxyl, amine, or carboxyl groups, which play crucial roles in enhancing binding specificity and affinity. The physicochemical properties of these inhibitors, such as molecular weight, polarity, and lipophilicity, are carefully optimized to balance solubility, permeability, and binding affinity. Hydrophobic regions within the inhibitor often interact with non-polar regions of the Trav3n-3 protein, while hydrophilic groups can enhance the solubility and allow for hydrogen bonding or electrostatic interactions with polar residues. The design of Trav3n-3 inhibitors is focused on achieving an optimal interaction with the target protein, ensuring a stable and efficient binding that can modulate the protein's activity under different environmental conditions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
AG-490 | 133550-30-8 | sc-202046C sc-202046A sc-202046B sc-202046 | 5 mg 50 mg 25 mg 10 mg | $82.00 $323.00 $219.00 $85.00 | 35 | |
AG-490 inhibits the JAK/STAT signaling pathway, which Trav3n-3 may rely on for activation or downstream signaling. Inhibition of this pathway prevents Trav3n-3 from exerting its effects if it is involved in signal transduction related to JAK/STAT. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, this compound reduces AKT phosphorylation, which in turn could lead to reduced activation of downstream proteins that are critical for Trav3n-3 function, resulting in its inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and the resulting complex inhibits mTOR, a kinase involved in cell growth and proliferation. If Trav3n-3 is implicated in these processes, mTOR inhibition would suppress Trav3n-3's functional role. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase. If Trav3n-3's activity is dependent on the p38 MAPK pathway for signal transduction or regulation, inhibition by SB203580 would suppress Trav3n-3's function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor, which blocks the MAPK/ERK pathway. If Trav3n-3 requires ERK activation to function, then PD98059 would inhibit Trav3n-3 by preventing its necessary ERK-mediated activation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK signaling pathways. Inhibition of JNK would prevent activation of transcription factors and other proteins that could be crucial for Trav3n-3's function, thereby inhibiting it. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 selectively inhibits MEK1/2, another key component of the MAPK/ERK pathway. By inhibiting MEK, U0126 would block the activation of ERK and thus prevent the functional activity of Trav3n-3 if it is ERK-dependent. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, leading to a reduction in AKT activation. If Trav3n-3 requires PI3K/AKT signaling for its activity, the inhibition by wortmannin would result in functional inhibition of Trav3n-3. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. If Trav3n-3's activity is contingent upon Src kinase signaling, dasatinib would inhibit those Src family kinases and therefore inhibit Trav3n-3's activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib inhibits certain tyrosine kinases, including Bcr-Abl and c-Kit. If Trav3n-3 is functionally dependent on the activity of these kinases, then imatinib would inhibit Trav3n-3 by inhibiting its associated kinases. | ||||||